Literature DB >> 31107850

Standardized Laparoscopic Sphincter-preserving Total Mesorectal Excision For Rectal Cancer: Median of 10 Years' Long-term Oncologic Outcome in 217 Unselected Consecutive Patients.

Suleyman Bademler1, Kadir B Koza2, Muhammed Z Ucuncu3, Handan Tokmak2, Baris Bakir4, Ethem N Oral5, Oktar Asoglu2.   

Abstract

This study was designed to evaluate the impact of a standardized laparoscopic total mesorectal excision (TME) on the long-term oncologic outcome. Unselected consecutive patients with rectal cancer underwent a standardized laparoscopic TME with medial to lateral approach encompassing 9 sequential steps. From 2005 to June 2012, laparoscopic sphincter-preserving TME was attempted in 217 patients. Mean follow-up of all patients was a median of 91 months (range, 3 to 164 mo). The local recurrence rate was 6.5%, and the distant recurrence rate was 19.8%. The 10-year disease-free survival (DFS) rates were 76.4% and overall survival (OS) was 67.1%. In the converted group, DFS and OS were 50% and 46.7%, respectively. In the laparoscopic group, DFS and OS were 78.3% and 68.5%, respectively. A standardized laparoscopic sphincter-preserving TME resulted in a favorable long-term oncologic outcome in unselected patients with rectal cancer. Conversion to open surgery has impaired OS and DFS.

Entities:  

Mesh:

Year:  2019        PMID: 31107850     DOI: 10.1097/SLE.0000000000000664

Source DB:  PubMed          Journal:  Surg Laparosc Endosc Percutan Tech        ISSN: 1530-4515            Impact factor:   1.719


  2 in total

1.  Is robotic da Vinci Xi® superior to the da Vinci Si® for sphincter-preserving total mesorectal excision? Outcomes in 150 mid-low rectal cancer patients.

Authors:  Vusal Aliyev; Naciye Cigdem Arslan; Beslen Goksoy; Koray Guven; Suha Goksel; Oktar Asoglu
Journal:  J Robot Surg       Date:  2022-02-02

2.  Short- and mid-term outcomes of transanal versus laparoscopic total mesorectal excision for low rectal cancer: a meta-analysis.

Authors:  Jingqing Ren; Huixing Luo; Shaojie Liu; Bailin Wang; Fan Wu
Journal:  Ann Surg Treat Res       Date:  2021-02-01       Impact factor: 1.859

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.